NCT02489695View on ClinicalTrials.gov

Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Papillary Renal Cell Carcinoma
Interventions
DRUG

Axitinib

axitinib 10mg twice a day

Trial Locations (10)

13273

Institut Paoli Calmettes, Marseille

14076

Centre Francois Baclesse, Caen

21079

Centre Geogres François Leclerc, Dijon

31059

Institut Claudius Regaud, Toulouse

33075

Chu Bordeaux, Bordeaux

44805

ICO - René Gauducheau, Saint-Herblain

49933

ICO Paul Papin, Angers

54519

ICL, Vandœuvre-lès-Nancy

69373

Centre Leon Berard, Lyon

94805

Gustave Roussy, Villejuif

All Listed Sponsors
lead

Centre Leon Berard

OTHER

NCT02489695 - Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter